BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
RMAT Designation Granted by FDA During Bleeding Disorders Awareness Month
SAN RAFAEL, Calif., March 8, 2021 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administrat... Biopharmaceuticals, FDA BioMarin, Valoctocogene Roxaparvovec, Hemophilia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Bleeding | Gene Therapy | Genetics | Haemophilia | Hemophilia | Marketing | Pharmaceuticals